Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

May

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

AI Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients

Sex Disparities Identified in Fatigue and Depression for Cancer Survivors

AI-Driven Model For Identifying Cancer Cachexia

Topical BRAF Inhibitor Under Study for Managing Acneiform Rash

Molecularly Selected, Tumor-Agnostic Phase II Trial Focuses on Combination Therapy